Kalvista Pharmaceuticals (NASDAQ:KALV) Releases Earnings Results

Kalvista Pharmaceuticals (NASDAQ:KALV) posted its quarterly earnings results on Monday. The specialty pharmaceutical company reported ($0.42) earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of ($0.62) by $0.20, Fidelity Earnings reports. Kalvista Pharmaceuticals had a negative net margin of 127.20% and a negative return on equity of 24.57%. The company had revenue of $3.37 million for the quarter, compared to the consensus estimate of $3.24 million.

NASDAQ KALV traded up $0.05 on Tuesday, hitting $16.65. The stock had a trading volume of 4,463 shares, compared to its average volume of 72,648. Kalvista Pharmaceuticals has a one year low of $14.50 and a one year high of $34.92. The stock has a market cap of $296.70 million, a price-to-earnings ratio of -12.07 and a beta of 2.11. The company’s 50-day moving average is $16.09 and its two-hundred day moving average is $21.42.

In other Kalvista Pharmaceuticals news, Director Albert Cha purchased 61,280 shares of the firm’s stock in a transaction dated Friday, July 19th. The stock was bought at an average price of $17.79 per share, with a total value of $1,090,171.20. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, CEO Thomas Andrew Crockett sold 10,000 shares of the stock in a transaction on Monday, July 15th. The stock was sold at an average price of $17.04, for a total value of $170,400.00. Following the completion of the transaction, the chief executive officer now directly owns 248,510 shares of the company’s stock, valued at approximately $4,234,610.40. The disclosure for this sale can be found here. Insiders acquired 145,427 shares of company stock worth $2,515,550 in the last 90 days. 21.60% of the stock is owned by company insiders.

Several equities research analysts recently weighed in on KALV shares. TheStreet lowered shares of Kalvista Pharmaceuticals from a “c-” rating to a “d+” rating in a research note on Thursday, July 11th. Svb Leerink began coverage on Kalvista Pharmaceuticals in a report on Monday, July 29th. They set an “outperform” rating and a $31.00 target price for the company. ValuEngine cut Kalvista Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Tuesday, July 2nd. Zacks Investment Research downgraded Kalvista Pharmaceuticals from a “buy” rating to a “sell” rating in a report on Wednesday, July 17th. Finally, Leerink Swann started coverage on Kalvista Pharmaceuticals in a research report on Monday, July 29th. They set an “outperform” rating and a $31.00 price objective for the company. Two investment analysts have rated the stock with a sell rating, one has assigned a hold rating and seven have given a buy rating to the company. The stock has an average rating of “Buy” and an average target price of $29.86.

Kalvista Pharmaceuticals Company Profile

KalVista Pharmaceuticals, Inc, a clinical stage pharmaceutical company, discovers, develops, and commercializes small molecule protease inhibitors. The company's product portfolio comprises small molecule plasma kallikrein inhibitors targeting hereditary angioedema (HAE) and diabetic macular edema (DME); and oral plasma kallikrein inhibitors.

Read More: Diversification Important in Investing

Earnings History for Kalvista Pharmaceuticals (NASDAQ:KALV)

Receive News & Ratings for Kalvista Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kalvista Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.